Analysis of liver fibrosis for chronic liver disease by the microbubble contrast agents

Analysis of liver fibrosis for chronic liver disease by the microbubble contrast agents - Assessment of liver fibrosis by the microbubble agents

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015387

Enrollment

120

Registered

2014-10-10

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease

Interventions

Microbubble contrast agents

Sonazoid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with chronic hepatitis or cirrhosis who were planned to receive liver biopsy (percutaneous or transvenous) 2. Having received adequate explanation of the contents of the trial and given their written consent

Exclusion criteria

Exclusion criteria: 1. Egg allergy 2. Severe lung disease 3. Severe heart disease 4. Determined to be ineligible by the physician in charge for any other reason

Design outcomes

Primary

Measure	Time frame
To compare fibrosis stages of liver specimens with contrast parameters which were the ratio between portal vein and liver parenchyma, and the time interval from the onset of contrast enhancement in portal vein to the time of the maximum intensity ratio	—

Countries

Japan

Contacts

Public ContactHitoshi Maruyama

Chiba University Graduate School of Medicine Department of Gastroenterology and Nephrology

maru-cib@umin.ac.jp043-226-2083

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026